SCHEMBL1287489

SCHEMBL1287489

CCc1cc2cc(F)ccc2o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
APP P05067 1/20 0.41
IDO1 P14902 2/20 0.38
CHRM2 P08172 2/20 0.38
CHRM4 P08173 2/20 0.38
CHRM5 P08912 2/20 0.38
CHRM1 P11229 2/20 0.38
CHRM3 P20309 2/20 0.38
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
HDAC3 O15379 2/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC2 Q92769 2/20 0.37
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
LOXL2 Q9Y4K0 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12967200 0.85 APP (0.41) APPHDAC3HDAC1HDAC2HDAC8
SCHEMBL2327940 0.82 TLR8 (0.43) CA12CA1CA2CA9APP
SCHEMBL20559454 0.81 LOXL2 (0.58) CA12CA1CA2CA9APP
SCHEMBL123183 0.81 CA12 (0.42) CA12CA1CA2CA9APP
SCHEMBL2095179 0.81 CA12 (0.42) CA12CA1CA2CA9APP
SCHEMBL17193880 0.81 CA12 (0.42) CA12CA1CA2CA9APP
SCHEMBL120404 0.81 IDO1 (0.53) CA12CA1CA2CA9APP
SCHEMBL13265520 0.78 CYP1A2 (0.45) CA12CA1CA2CA9F2
SCHEMBL11559549 0.78 MAOB (0.49) CA12CA1CA2CA9APP
SCHEMBL14455719 0.77 F2 (0.38) F2F10HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210163471-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS 2021-06-03 US disclosed
CN-106065010-B For treating or preventing the compound of hyperuricemia or gout 镇江新元素医药科技有限公司 2019-01-01 CN disclosed
US-10005750-B2 Developing potent urate transporter inhibitors: compounds designed for their uricosuric action J-PHARMA CO., LTD. (JP) 2018-06-26 US disclosed
CN-106065010-A For treating or prevent the compound of hyperuricemia or gout 镇江新元素医药科技有限公司 2016-11-02 CN disclosed
US-9309260-B2 Inhibitors of hepatitis C virus PRESIDIO PHARMACEUTICALS, INC. (US) 2016-04-12 US disclosed
US-9085587-B2 Inhibitors of hepatitis C virus PRESIDIO PHARMACEUTICALS, INC. (US) 2015-07-21 US disclosed
US-20130302282-A1 Inhibitors of Hepatitis C Virus PRESIDIO PHARMACEUTICALS, INC. (US) 2013-11-14 US disclosed
US-20130225673-A1 DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION J-PHARMA CO., LTD. (JP) 2013-08-29 US disclosed
US-20120276051-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. (US) 2012-11-01 US disclosed
CN-102718735-A 2-ethyl-3-(4-hydroxy) benzoyl benzofuran compounds and compositions and preparation methods of compounds UNIV SHENYANG PHARMACEUTICAL 2012-10-10 CN disclosed
US-20120251497-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. 2012-10-04 US disclosed
US-20120190639-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2012-07-26 US disclosed
WO-2012048058-A2 DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION J-PHARMA CO., LTD. (JP) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120276051-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, LIPC, HCCS CA12 3562/4885CA1 4292/4885CA2 4648/4885
US-10005750-B2 Developing potent urate transporter inhibitors: compounds designed for their uricosuric action SLCO2B1, SLCO2A1, SLC10A6 CA12 634/4885CA1 1136/4885CA2 592/4885
US-20210163471-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME GRN, PRNP, PSEN1 CA12 4672/4885CA1 4515/4885CA2 4850/4885
US-20120190639-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 CA12 2622/4885CA1 3263/4885CA2 2188/4885
US-20130302282-A1 Inhibitors of Hepatitis C Virus HAVCR2, LIPC, HCCS CA12 3562/4885CA1 4292/4885CA2 4648/4885
US-20130225673-A1 DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION SLCO2B1, SLCO2A1, SLC10A6 CA12 634/4885CA1 1136/4885CA2 592/4885
US-20120251497-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, LIPC, HCCS CA12 3562/4885CA1 4292/4885CA2 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.